About Us

MetaHeps

MetaHeps® has an ex-vivo blood test to exclude or clearly identify DILI in a patient with liver injury. It can also identify the causal drug of the DILI especially in a complex polymedication situation. MetaHeps thereby helps BioPharmaceutical companies and CROs to solve the risks of DILI for drugs in clinical development and in the market. All in an unrivalled way.

The vision of MetaHeps® is to increase access of patients to novel and existing drugs by quickly solving and preventing DILI issues in an unrivaled and innovative approach.

MetaHeps® was founded in 2014 by leading hepatology experts as a spin-off from the university hospital Grosshadern of the LMU, Munich, Germany. It has a strong IP position in the US, EU and in Japan.

MetaHeps has the only technology and solution to exclude DILI or identify which drug caused DILI to:

  • avoid financial losses due to unnecessary drug development attrition and market withdrawals
  • improve benefit-risk assessment by providing unprecedented data on DILI cases and their individual cause
  • reduce risks of drug development and provide patients access to urgently needed treatments
  • protect patients at risk by the development of novel biomarkers

MetaHeps® brings clear benefits to Patients, Clinicians, Hospitals, Pharmaceutical and Biotech companies, Clinical Research Organizations (CRO), Clinical Research and Development, Pharmacovigilance and external PV service providers, Drug safety.

MetaHeps® has an ex-vivo blood test to exclude or clearly identify DILI in a patient with liver injury. It can also identify the causal drug of the DILI especially in a complex polymedication situation. MetaHeps thereby helps BioPharmaceutical companies and CROs to solve the risks of DILI for drugs in clinical development and in the market. All in an unrivalled way.

The vision of MetaHeps® is to increase access of patients to novel and existing drugs by quickly solving and preventing DILI issues in an unrivaled and innovative approach.

MetaHeps® was founded in 2014 by leading hepatology experts as a spin-off from the university hospital Grosshadern of the LMU, Munich, Germany. It has a strong IP position in the US, EU and in Japan.

MetaHeps has the only technology and solution to exclude DILI or identify which drug caused DILI to:

  • support patients receiving important drug treatments by early clarification of the cause of their DILI
  • improve benefit-risk assessment by providing unprecedented data on DILI cases and their individual cause
  • avoid financial losses due to unnecessary drug development attrition and market withdrawals
  • reduce risks of drug development and provide patients access to urgently needed treatments
  • protect patients at risk by the development of novel biomarkers

MetaHeps® brings clear benefits to Patients, Clinicians, Hospitals, Pharmaceutical and Biotech companies, Clinical Research Organizations (CRO), Clinical Research and Development, Pharmacovigilance and external PV service providers, Drug safety.

Leadership

Dr. Lucio A.A. van Rooijen

CEO

30+ years of leadership experience and expertise in Life Science and Bio Pharma industries and strong corporate development track record in start-up, mid-tier and large corporate Bio Pharma companies.

Prof. Dr. Alexander Gerbes

NED, Founder, Scientific Advisor​

Medical Doctor & co-founder, director of the Liver Centre at the LMU, Munich and an internationally renowned expert in clinical and experimental hepatology. ​

Stefan Bartsch

NED, Founder, Business Advisor​

Investor & business advisor, international negotiations experience from 25 years in finance with Siemens.

Networks, Awards

MetaHeps is partner of a number of international networks.

The international Consortium to develop novel biomarkers, consisting of leading pharmaceutical companies and universities.

MetaHeps research and development of its innovative and patented test has been supported by a number of local, federal and international grants and awards, including: